AU2001288260A1 - Neutrokine-alpha and neutrokine-alpha splice variant - Google Patents
Neutrokine-alpha and neutrokine-alpha splice variantInfo
- Publication number
- AU2001288260A1 AU2001288260A1 AU2001288260A AU8826001A AU2001288260A1 AU 2001288260 A1 AU2001288260 A1 AU 2001288260A1 AU 2001288260 A AU2001288260 A AU 2001288260A AU 8826001 A AU8826001 A AU 8826001A AU 2001288260 A1 AU2001288260 A1 AU 2001288260A1
- Authority
- AU
- Australia
- Prior art keywords
- neutrokine
- alpha
- splice variant
- variant
- alpha splice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Rehabilitation Therapy (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22562800P | 2000-08-15 | 2000-08-15 | |
US60/225,628 | 2000-08-15 | ||
US22700800P | 2000-08-23 | 2000-08-23 | |
US60/227,008 | 2000-08-23 | ||
US23433800P | 2000-09-22 | 2000-09-22 | |
US60/234,338 | 2000-09-22 | ||
US24080600P | 2000-10-17 | 2000-10-17 | |
US60/240,806 | 2000-10-17 | ||
US25002000P | 2000-11-30 | 2000-11-30 | |
US60/250,020 | 2000-11-30 | ||
US27624801P | 2001-03-16 | 2001-03-16 | |
US60/276,248 | 2001-03-16 | ||
US29349901P | 2001-05-25 | 2001-05-25 | |
US60/293,499 | 2001-05-25 | ||
US29612201P | 2001-06-07 | 2001-06-07 | |
US60/296,122 | 2001-06-07 | ||
US30480901P | 2001-07-13 | 2001-07-13 | |
US60/304,809 | 2001-07-13 | ||
PCT/US2001/025549 WO2002018620A2 (en) | 2000-08-15 | 2001-08-15 | Neutrokine-alpha and neutrokine-alpha splice variant |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001288260A1 true AU2001288260A1 (en) | 2002-03-13 |
Family
ID=27578713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001288260A Abandoned AU2001288260A1 (en) | 2000-08-15 | 2001-08-15 | Neutrokine-alpha and neutrokine-alpha splice variant |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1309718A4 (en) |
AU (1) | AU2001288260A1 (en) |
CA (1) | CA2419661A1 (en) |
WO (1) | WO2002018620A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
EP2298332B1 (en) | 1999-01-25 | 2015-07-08 | Biogen MA Inc. | BAFF, inhibitors thereof and their use in the modulation of the B-cell response |
BRPI0013391B8 (en) | 1999-08-17 | 2021-05-25 | Apotech R&D S A | use of bcma polypeptides in the preparation of a pharmaceutical composition to treat an autoimmune disease or a b-cell lymphoproliferative disorder |
UA74798C2 (en) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors |
EP2281843B1 (en) | 2000-06-16 | 2016-10-12 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
UA83458C2 (en) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf) |
AU2002351495A1 (en) * | 2001-10-17 | 2003-04-28 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
US7553930B2 (en) | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
US20050130892A1 (en) * | 2003-03-07 | 2005-06-16 | Xencor, Inc. | BAFF variants and methods thereof |
EP1606312A2 (en) * | 2003-03-07 | 2005-12-21 | Xencor Inc. | Baff mutants with at least one amino acid substitution and methods of their production |
EP1608730B1 (en) | 2003-03-28 | 2013-11-06 | Biogen Idec MA Inc. | Truncated baff receptors |
US6987270B2 (en) | 2003-05-07 | 2006-01-17 | General Electric Company | Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes |
JP2007526220A (en) | 2003-06-05 | 2007-09-13 | ジェネンテック・インコーポレーテッド | Combination therapy for B cell disease |
EP1814577B1 (en) | 2004-10-13 | 2014-04-23 | The Washington University | Use of baff to treat sepsis |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
US9726673B2 (en) | 2005-11-23 | 2017-08-08 | Genentech, Inc. | Methods and compositions related to B cell assays |
WO2007123765A2 (en) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
GB201317929D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2230307A1 (en) * | 1996-10-25 | 2010-09-22 | Human Genome Sciences, Inc. | Neutrokine alpha |
AU5705898A (en) * | 1996-12-17 | 1998-07-15 | Schering Corporation | Mammalian cell surface antigens; related reagents |
EA200000311A1 (en) * | 1997-09-12 | 2000-10-30 | Апотек Р Энд Д Са | NEW PROTEIN IMMUNE SYSTEM - KAU |
AU2212299A (en) * | 1998-01-05 | 1999-07-26 | Genentech Inc. | Compositions and methods for the treatment of tumor |
-
2001
- 2001-08-15 CA CA002419661A patent/CA2419661A1/en not_active Abandoned
- 2001-08-15 WO PCT/US2001/025549 patent/WO2002018620A2/en not_active Application Discontinuation
- 2001-08-15 AU AU2001288260A patent/AU2001288260A1/en not_active Abandoned
- 2001-08-15 EP EP01967981A patent/EP1309718A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2002018620A2 (en) | 2002-03-07 |
EP1309718A4 (en) | 2004-08-25 |
EP1309718A2 (en) | 2003-05-14 |
WO2002018620A3 (en) | 2003-03-20 |
CA2419661A1 (en) | 2002-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1157110A4 (en) | Neutrokine-alpha and neutrokine-alpha splice variant | |
AU2001288260A1 (en) | Neutrokine-alpha and neutrokine-alpha splice variant | |
AU2002235128A1 (en) | Expression miniarrays and uses thereof | |
WO2002017157A8 (en) | Marketing systems and methods | |
AU2001242763A1 (en) | Advertising system | |
AU3620600A (en) | Skin-marking devices and their use | |
AU2002243246A1 (en) | Cddo-compounds and combination therapies thereof | |
AU2002351495A1 (en) | Neutrokine-alpha and neutrokine-alpha splice variant | |
AU2001280599A1 (en) | Compounds and methods | |
AU2001253418A1 (en) | Compounds and methods | |
AU2002211717A1 (en) | Stresscopins and their uses | |
AUPQ555400A0 (en) | Laser system and methods | |
AU2001281636A1 (en) | Advertising | |
AU2001292936A1 (en) | Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines | |
AU2001243394A1 (en) | Compounds and methods | |
AU2001286400A1 (en) | Fiber formulation | |
AU2001229439A1 (en) | Bioconjugates and uses thereof | |
AU2001295185A1 (en) | Multiplexing-interleaving and demultiplexing-deinterleaving | |
AUPQ872300A0 (en) | Compounds and methods | |
AU3732500A (en) | Beclin and uses thereof | |
AU2001278951A1 (en) | Compounds and methods | |
AU4432001A (en) | Trityl-type compounds and their use | |
AU2002227019A1 (en) | Cashcalling and voicemining system | |
AU2001252062A1 (en) | Steatosis-modulating factors and uses thereof | |
AU2002256556A1 (en) | Sea-trosy and related methods |